Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 117Carcinoma, Transitional Cell 39Testicular Neoplasms 23Urethral Neoplasms 18Testicular Germ Cell Tumor 14Ovarian Neoplasms 13Teratoma 12Prostatic Neoplasms 11Endodermal Sinus Tumor 11Seminoma 10Neoplasms 10Carcinoma, Embryonal 9Ureteral Neoplasms 8Melanoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Renal Cell 7Stomach Neoplasms 6Penile Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Breast Neoplasms 6Urologic Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Urothelial Cancer 4Lung Neoplasms 4Central Nervous System Neoplasms 4Wilms Tumor 3Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3

Interventions

sodium thiosulfate 1Platinum 1Magnetic Resonance Spectroscopy 1Hearing 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hearing Loss × Cisplatin × Genitourinary × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡